| scholarly article | Q13442814 |
| P2093 | author name string | D. C. Montefiori | |
| M. Mancini | |||
| P. Tiollais | |||
| M. L. Michel | |||
| Y. Rivière | |||
| K. Schlienger | |||
| P2860 | cites work | Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene | Q41699910 |
| Vaccine protection of rhesus macaques against simian immunodeficiency virus infection | Q41717021 | ||
| Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera | Q41722321 | ||
| A formalin-inactivated whole SIV vaccine confers protection in macaques | Q42188961 | ||
| A rapid and simple colorimetric test for the study of anti-HIV agents | Q42813565 | ||
| Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys | Q43414762 | ||
| Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination | Q43939161 | ||
| Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. | Q44455932 | ||
| Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies | Q44683552 | ||
| AIDS vaccine developments | Q45009094 | ||
| International Collaboration Comparing Neutralization and Binding Assays for Monoclonal Antibodies to Simian Immunodeficiency Virus | Q45786878 | ||
| Identification of four antibody-binding sites in the envelope proteins of simian immunodeficiency virus, SIVsm. | Q45787013 | ||
| Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): Correlation with biological activities | Q45804494 | ||
| Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine | Q45853459 | ||
| Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins | Q45865515 | ||
| Identification of broadly reactive continuous antigenic determinants of simian immunodeficiency virus glycoproteins | Q45872768 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses | Q46796894 | ||
| Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region | Q48248301 | ||
| Transmission of HTLV-III Infection from Human Plasma to Chimpanzees: An Animal Model for AIDS | Q52849903 | ||
| Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. | Q53436850 | ||
| AIDS vaccine developments | Q56838054 | ||
| AIDS vaccine developments | Q59028032 | ||
| Anti-cell antibody in macaques | Q59098168 | ||
| Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection | Q67967877 | ||
| Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines | Q67972576 | ||
| Relation of phenotype evolution of HIV-1 to envelope V2 configuration | Q70739957 | ||
| Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection | Q71607823 | ||
| Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials | Q72672957 | ||
| Antigenic structure of hepatitis B surface antigen: identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies | Q72720705 | ||
| Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 | Q28646835 | ||
| The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein | Q30405844 | ||
| Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. | Q31171196 | ||
| Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene | Q33196552 | ||
| Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles | Q33660809 | ||
| Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates | Q33933855 | ||
| Isolation of T-cell tropic HTLV-III-like retrovirus from macaques | Q34049156 | ||
| Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. | Q34214455 | ||
| Vaccine protection against simian immunodeficiency virus infection | Q34298187 | ||
| Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. | Q35016588 | ||
| Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. | Q36626986 | ||
| Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines | Q36630114 | ||
| Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. | Q36640342 | ||
| Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation | Q36647416 | ||
| Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. | Q36649240 | ||
| Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys | Q36650125 | ||
| Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains | Q36653730 | ||
| Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 | Q36690500 | ||
| Characterization of B-Cell Epitopes in the Envelope Glycoproteins of Simian Immunodeficiency Virus | Q36695972 | ||
| Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. | Q36812220 | ||
| Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins | Q36827554 | ||
| The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1 | Q36839199 | ||
| Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome | Q36860939 | ||
| Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge | Q36886112 | ||
| Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus | Q37375345 | ||
| Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences | Q37577555 | ||
| Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin | Q37579934 | ||
| Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody | Q37603996 | ||
| Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. | Q39143639 | ||
| T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles | Q40109002 | ||
| Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | Q40308974 | ||
| Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies | Q41621929 | ||
| Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins | Q41677477 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Simian immunodeficiency virus | Q1890246 |
| P304 | page(s) | 6578-6588 | |
| P577 | publication date | 1994-10-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge | |
| P478 | volume | 68 |
| Q39879382 | Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. |
| Q39577967 | Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus |
| Q35839932 | Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines |
| Q39642374 | Identification of highly attenuated mutants of simian immunodeficiency virus |
| Q35897786 | Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. |
| Q33852720 | Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors |
| Q35838430 | Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype. |
| Q33810277 | Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus |
| Q39874667 | Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. |
| Q35848231 | Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) |
| Q39591825 | Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein |
Search more.